Overview

Preventing Frequent Sinus Infections in HIV-Infected Patients

Status:
Withdrawn
Trial end date:
1993-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the additional effectiveness of an anti-inflammatory nasal spray ( beclomethasone dipropionate ) and a broad spectrum antibiotic ( cefuroxime axetil ) over decongestant ( Deconsal II ) alone, when these agents are given individually or in combination for the prevention of recurrent paranasal sinus infection in patients with HIV infection. To compare the clinical utility of paranasal sinus radiographs with computed tomograms (CTs) in the evaluation and management of HIV-infected patients with recurrent paranasal sinus infection. To determine relevant prognostic factors and the microbiologic etiology of maxillary sinusitis in this patient population. Sinusitis is common among HIV-infected patients and is likely to be recurrent or refractory to traditional therapy, particularly in patients with advanced immunosuppression. An intervention aimed at prevention of recurrent sinus disease in HIV-infected patients appears to be warranted.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Adams Laboratories
Glaxo Wellcome
Treatments:
Beclomethasone
Cefuroxime
Cefuroxime axetil
Chlorpheniramine, phenylpropanolamine drug combination
Ephedrine
Guaifenesin
Phenylpropanolamine
Pseudoephedrine